147 related articles for article (PubMed ID: 38780174)
1. Patient-Centered Rocket Science: Accurate but Imprecise.
Bakal JA; Wilber D
J Am Heart Assoc; 2024 Jun; 13(11):e035100. PubMed ID: 38780174
[No Abstract] [Full Text] [Related]
2. Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF Analysis.
Harrington J; Hellkamp AS; Mahaffey KW; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Fox KAA; Singer DE; Goodman SG; Patel MR; Piccini JP
J Am Heart Assoc; 2024 Jun; 13(11):e028951. PubMed ID: 38780169
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of Rivaroxaban Following Different Dosage Criteria (ROCKET AF or J-ROCKET AF Trials) in Asian Patients With Atrial Fibrillation.
Chan YH; Lee HF; Wang CL; Chang SH; Yeh CH; Chao TF; Yeh YH; Chen SA; Kuo CT
J Am Heart Assoc; 2019 Nov; 8(21):e013053. PubMed ID: 31623498
[TBL] [Abstract][Full Text] [Related]
4. Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.
Camm AJ; Amarenco P; Haas S; Hess S; Kirchhof P; Lambelet M; Bach M; Turpie AGG
Europace; 2019 Mar; 21(3):421-427. PubMed ID: 30052894
[TBL] [Abstract][Full Text] [Related]
5. Warfarin for prevention of thromboembolism in atrial fibrillation: comparison of patient characteristics and outcomes of the "Real-World" Michigan Anticoagulation Quality Improvement Initiative (MAQI
Hughey AB; Gu X; Haymart B; Kline-Rogers E; Almany S; Kozlowski J; Besley D; Krol GD; Ahsan S; Kaatz S; Froehlich JB; Barnes GD
J Thromb Thrombolysis; 2018 Oct; 46(3):316-324. PubMed ID: 29948756
[TBL] [Abstract][Full Text] [Related]
6. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
[TBL] [Abstract][Full Text] [Related]
7. Comparisons of effectiveness and safety between on-label dosing, off-label underdosing, and off-label overdosing in Asian and non-Asian atrial fibrillation patients treated with rivaroxaban: a systematic review and meta-analysis of observational studies.
Chan YH; Chan CY; Chen SW; Chao TF; Lip GYH
Europace; 2023 Oct; 25(10):. PubMed ID: 37738425
[TBL] [Abstract][Full Text] [Related]
8. Comparing the imperfect with the imperfect: the imprecise science of assessing the risk and benefits of anticoagulation in atrial fibrillation.
Tan AY; Ellenbogen KA
Circulation; 2014 May; 129(20):1997-9. PubMed ID: 24682386
[No Abstract] [Full Text] [Related]
9. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
[TBL] [Abstract][Full Text] [Related]
10. Rivaroxaban in patients with atrial fibrillation: from ROCKET AF to everyday practice.
Barón-Esquivias G; Marín F; Sanmartín Fernandez M
Expert Rev Cardiovasc Ther; 2017 May; 15(5):403-413. PubMed ID: 28319424
[TBL] [Abstract][Full Text] [Related]
11. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled clinical trials versus real-life atrial fibrillation patients treated with oral anticoagulants. Do we treat the same patients?
Balsam P; Tymińska A; Ozierański K; Zaleska M; Żukowska K; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Kołtowski Ł; Praska-Ogińska A; Zaboyska I; Bednarski J; Filipiak KJ; Opolski G
Cardiol J; 2020; 27(5):590-599. PubMed ID: 30406937
[TBL] [Abstract][Full Text] [Related]
13. Simulation of anticoagulation in atrial fibrillation patients with rivaroxaban-from trial to target population.
Zhang C; Wang WW; Pan MM; Gu ZC
Rev Cardiovasc Med; 2021 Sep; 22(3):1019-1027. PubMed ID: 34565103
[TBL] [Abstract][Full Text] [Related]
14. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex.
Carnicelli AP; Hong H; Connolly SJ; Eikelboom J; Giugliano RP; Morrow DA; Patel MR; Wallentin L; Alexander JH; Cecilia Bahit M; Benz AP; Bohula EA; Chao TF; Dyal L; Ezekowitz M; A A Fox K; Gencer B; Halperin JL; Hijazi Z; Hohnloser SH; Hua K; Hylek E; Toda Kato E; Kuder J; Lopes RD; Mahaffey KW; Oldgren J; Piccini JP; Ruff CT; Steffel J; Wojdyla D; Granger CB;
Circulation; 2022 Jan; 145(4):242-255. PubMed ID: 34985309
[TBL] [Abstract][Full Text] [Related]
15. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –.
Hori M; Matsumoto M; Tanahashi N; Momomura S; Uchiyama S; Goto S; Izumi T; Koretsune Y; Kajikawa M; Kato M; Ueda H; Iwamoto K; Tajiri M;
Circ J; 2012; 76(9):2104-11. PubMed ID: 22664783
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
[TBL] [Abstract][Full Text] [Related]
17. Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Clinical Practice: Focus on Rivaroxaban in Stroke Prevention in Patients With Atrial Fibrillation.
Sanmartín-Fernández M; Marzal-Martín D
Clin Appl Thromb Hemost; 2017 Oct; 23(7):711-724. PubMed ID: 27624737
[TBL] [Abstract][Full Text] [Related]
18. Critical appraisal of network meta-analyses evaluating the efficacy and safety of new oral anticoagulants in atrial fibrillation stroke prevention trials.
Cope S; Clemens A; Hammès F; Noack H; Jansen JP
Value Health; 2015 Mar; 18(2):234-49. PubMed ID: 25773559
[TBL] [Abstract][Full Text] [Related]
19. Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials.
Deitelzweig S; Amin A; Jing Y; Makenbaeva D; Wiederkehr D; Lin J; Graham J
J Med Econ; 2012; 15(4):776-85. PubMed ID: 22449118
[TBL] [Abstract][Full Text] [Related]
20. Non-valvular atrial fibrillation: potential clinical implications of the heterogeneous definitions used in trials on new oral anticoagulants.
Boriani G; Cimaglia P; Fantecchi E; Mantovani V; Ziacchi M; Valzania C; Martignani C; Biffi M; Diemberger I
J Cardiovasc Med (Hagerstown); 2015 Jul; 16(7):491-6. PubMed ID: 25575278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
